60 Degrees Pharmaceuticals, Inc. (SXTP)
NASDAQ: SXTP · Real-Time Price · USD
2.910
-0.310 (-9.63%)
At close: Mar 12, 2026, 4:00 PM EDT
2.800
-0.110 (-3.78%)
After-hours: Mar 12, 2026, 7:59 PM EDT
SXTP Employees
60 Degrees Pharmaceuticals had 3 employees as of December 31, 2024. The number of employees did not change compared to the previous year.
Employees
3
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$454,982
Profits / Employee
-$2,825,188
Market Cap
3.75M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 3 | 0 | - |
| Dec 31, 2023 | 3 | 1 | 50.00% |
| Dec 31, 2022 | 2 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Jaguar Health | 49 |
| Scinai Immunotherapeutics | 31 |
| Lyra Therapeutics | 30 |
| Calidi Biotherapeutics | 28 |
| Enveric Biosciences | 6 |
| CDT Equity | 6 |
| Adial Pharmaceuticals | 5 |
| PMGC Holdings | 3 |
SXTP News
- 1 day ago - 60 Degrees Pharmaceuticals Announces All Patients Cured of Babesiosis After Tafenoquine Treatment in Expanded Use Clinical Trial - GlobeNewsWire
- 5 weeks ago - 60 Degrees Pharmaceuticals Expands Access to ARAKODA® with GoodRx Partnership - GlobeNewsWire
- 2 months ago - 60 Degrees Pharmaceuticals, Inc. Announces Approval of Reverse Stock Split Ratio - GlobeNewsWire
- 2 months ago - 60 Degrees Pharmaceuticals Announces Detection of Babesia Infection in 24 Percent of Patients Presenting with Chronic Fatigue in Peer-Reviewed, Sponsored Study at NC State - GlobeNewsWire
- 3 months ago - 60 Degrees Pharmaceuticals Announces Expansion of ARAKODA® Sales and Marketing in 2026 - GlobeNewsWire
- 3 months ago - 60 Degrees Pharmaceuticals Announces Clinical Site Now Open for Patient Enrollment for the B-FREE Chronic Babesiosis Study at Mount Sinai Icahn School of Medicine - GlobeNewsWire
- 4 months ago - 60 Degrees Pharmaceuticals Announces Third Quarter 2025 Results - GlobeNewsWire
- 5 months ago - 60 Degrees Pharmaceuticals Announces No Detection of Babesia Infection in First Patient Following Treatment with Tafenoquine in Relapsing Babesiosis Study - GlobeNewsWire